CTI BioPharma is a biopharmaceutical company whose mission is to acquire, develop and bring to market less toxic, more effective ways to treat and cure cancer. Our therapeutic focus is on novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. We have a commercial product, PIXUVRI®, available in certain markets in Europe, as well as a diverse late-stage development pipeline that we believe will drive future growth of our company. We are headquartered in Seattle, Washington, with offices in London and Milan. Our management and investor relations team provide updates throughout the year through conference calls, investor events, press releases and SEC filings. We invite you to sign up for our investor alerts and listen to our archived and live presentations.

To CTI’s knowledge, all press releases, scientific papers and abstracts, and the information contained within them were timely and accurate when issued. The continued accuracy of this material beyond the date of issuance and posting on the website is not assured. CTI has no intention of updating this information and specifically disclaims any duty to do so. These documents may contain forward-looking statements. Actual results could vary dramatically as a result of known and unknown risks and uncertainties. Please see Terms of Use for this website.

IR Contacts

  • Current Quote
  • Stock Chart
$2.44 + 0.01 (0.41%)
Day High:$2.51
Day Low:$2.36
12/19/144:00 p.m. ET
Delayed at least 15 minutes.

Monique Greer
T +1 206-272-4343
Ed Bell
T +1 206-272-4345

CTI Life Sciences Limited, Milan Branch
Laura Villa
T +1 39 02 94751572
T +1 206-272-4155 (U.S. only)

Recent News

Dec 09, 2014CTI BioPharma Announces Presentation of Data Demonstrating Pacritinib Overrides Stromal Mediated Resistance in FLT3-ITD Positive AML Cells
-Significant synergy resulted with combination treatment of pacritinib and cytarabine or a MEK inhibitor- SEATTLE, Dec. 9, 2014 /PRNewswire/ -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today announced data showing treatment with pacritinib, an investigational oral multikinase inhibitor in Phase 3 clinical development, preferentially killed acute myeloid leukemia (AML) cells with FLT3 mutations, overcame stromal protection and suppressed leukemic outgrowth from stroma adherent AML ce... 
Printer Friendly Version
Dec 06, 2014CTI BioPharma Announces Comprehensive Kinome Analysis that Demonstrates Pacritinib Inhibits Kinases Linked to a Spectrum of Blood-Related Cancers
-Profile Supports Potential Role in Modulating Tumor Microenvironment in Blood-Related Cancers, Including AML, MDS, CMML and CLL- -Analysis Also Provides Scientific Basis for Pacritinib's Lack of Myelosuppression, a Unique Attribute Among Agents in Development for Myelofibrosis- SEATTLE, Dec. 6, 2014 /PRNewswire/ -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today announced that an analysis of kinase inhibition by pacritinib, a next generation oral multikinase inhibitor in Phase 3 ... 
Printer Friendly Version
Dec 04, 2014CTI BioPharma Receives $15 Million Milestone Payment for TRISENOX®
SEATTLE, Dec. 4, 2014 /PRNewswire/ -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today announced that it has received a $15 million milestone payment from Teva Pharmaceutical Industries Ltd. (Teva) related to the achievement of sales milestones for TRISENOX® (arsenic trioxide). TRISENOX was acquired from CTI by Cephalon, Inc. (Cephalon). Cephalon was subsequently acquired by Teva. The milestone was paid pursuant to an acquisition agreement for TRISENOX entered into with Cephalon under whic... 
Printer Friendly Version


Dec 03, 2014
CTI BioPharma Corp at Piper Jaffray Healthcare Conference
Nov 19, 2014
CTI BioPharma Corp at Jefferies Global Heatlhcare Conference - London
Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.